Glassman Wealth Services continued to hold its position in shares of Becton, Dickinson and Company (NYSE:BDX) during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 799 shares of the medical instruments supplier’s stock at the close of the second quarter. Glassman Wealth Services’ holdings in Becton, Dickinson and were worth $156,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in BDX. Almanack Investment Partners LLC. bought a new stake in Becton, Dickinson and in the first quarter worth about $105,000. Parkside Financial Bank & Trust raised its position in Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after acquiring an additional 9 shares during the period. QCI Asset Management Inc. NY raised its position in Becton, Dickinson and by 9.2% in the first quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock worth $130,000 after acquiring an additional 60 shares during the period. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in Becton, Dickinson and by 55.8% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after acquiring an additional 240 shares during the period. Finally, Financial Architects Inc raised its position in Becton, Dickinson and by 8.0% in the second quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock worth $142,000 after acquiring an additional 54 shares during the period. Institutional investors and hedge funds own 87.12% of the company’s stock.

In related news, insider Thomas E. Polen, Jr. sold 5,971 shares of the firm’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total value of $1,178,735.11. Following the transaction, the insider now owns 12,861 shares of the company’s stock, valued at $2,538,890.01. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Ellen R. Strahlman sold 9,283 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the completion of the transaction, the insider now directly owns 26,638 shares in the company, valued at approximately $5,279,917.98. The disclosure for this sale can be found here. In the last three months, insiders sold 75,904 shares of company stock worth $15,242,688. 1.40% of the stock is currently owned by insiders.

WARNING: “Becton, Dickinson and Company (BDX) Stake Held by Glassman Wealth Services” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/becton-dickinson-and-company-bdx-stake-held-by-glassman-wealth-services/1609279.html.

Shares of Becton, Dickinson and Company (NYSE BDX) opened at 195.00 on Thursday. The company has a market cap of $44.37 billion, a price-to-earnings ratio of 56.47 and a beta of 1.05. The stock has a 50 day moving average of $197.37 and a 200 day moving average of $192.32. Becton, Dickinson and Company has a 52-week low of $161.29 and a 52-week high of $206.63.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.44 by $0.02. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm’s revenue was down 5.1% compared to the same quarter last year. During the same quarter last year, the firm posted $2.35 earnings per share. On average, equities research analysts expect that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 29th. Investors of record on Friday, September 8th were issued a $0.73 dividend. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.50%. The ex-dividend date of this dividend was Thursday, September 7th. Becton, Dickinson and’s payout ratio is 83.43%.

BDX has been the topic of several research reports. BidaskClub lowered shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Bank of America Corporation reaffirmed a “buy” rating and issued a $225.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. Zacks Investment Research raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective on the stock in a research report on Monday, July 17th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $213.00 price objective on shares of Becton, Dickinson and in a research report on Tuesday, September 12th. Five investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $200.93.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.